Wednesday, May 2

08:30 AM - 10:00 AM
Cell Processing Track Session 1 - Novel Cell Processing Technologies
Chair:
Sarah Nikiforow, MD, PhD, Dana Farber Cancer Institute, United States
Speakers:
Nirav Shah, MD, Medical College of Wisconsin, United States
Tony Ward, MBA, GPB Scientific, United States
Vittorio Sebastiano, PhD, Stanford School of Medicine, United States
08:30 AM - 10:00 AM
GRP Workshop Session 1 - Locally Developed Complex Immunotherapies for Global Supply
Moderator:
Dominic Wall, PhD, FFSc(RCPA), Peter MacCallum Cancer Centre, Australia
08:30 AM - 10:00 AM
ISCT-CBA Cord Blood Series Session 1 - Current Status of Cord Blood Transplantation
Speakers:
Joanne Kurtzberg, MD Duke University Medical Center, United States
Elizabeth J. Shpall, MD, MD Anderson Cancer Center, United States
08:30 AM - 10:00 AM
MSC Workshop Session 1 - Development of Potency Assays to Predict MSC Clinical Efficacy
Chair:
Don Phinney, PhD, The Scripps Research Institute, United States
Speakers:
Steven R. Bauer, PhD, U.S. Food and Drug Administration (FDA), United States
Massimo Dominici, MD, University of Modena and Reggio Emilia, Italy
08:30 AM - 10:00 AM
Canadian Cell Therapy Strategy Workshop Session 1 - Cell & Gene Therapy Manufacturing Infrastructure
08:30 AM - 10:00 AM
ISCT-FACT Quality Bootcamp Session 1
10:15 AM - 11:45 AM
Cell Processing Track Session 2 - Growth Areas in Novel Cell Therapy Quality Control and Release Testing
Chair:
David DiGiusto, PhD, Stanford Healthcare and Stanford School of Medicine, United States
Speakers:
Adrian Gee, PhD Baylor College of Medicine, United States
Lindsay Skrdlant, PhD, Stanford University School of Medicine, United States
10:15 AM - 11:45 AM
GRP Workshop Session 2 - CMC Considerations When Expanding the Market into Other Regions
Moderator:
Christopher Bravery, PhD, Consulting on Advanced Biologicals Limited, United Kingdom
10:15 AM - 11:45 AM
ISCT-CBA Cord Blood Series Session 2 - Cord Blood Immunotherapy
Speakers:
Catherine Bollard, MBChB, MD, Children's National Medical Center and The George Washington University, United States
Juliet Barker, MBBS, FRACP, Memorial Sloan Kettering Cancer Center, United States
10:15 AM - 11:45 AM
MSC Workshop Session 2 - Methods to Improve MSC Engraftment and Potency In Vivo
Chair:
Jan Nolta, PhD, UC Davis Stem Cell Program, United States
Speakers:
Armand Keating, MD, Princess Margaret Hospital, Canada
10:15 AM - 11:45 AM
Canadian Cell Therapy Strategy Workshop Session 2 - Investment in Canada: The Global Advantage
10:15 AM - 11:45 AM
ISCT-FACT Quality Bootcamp Session 2
01:00 PM - 02:30 PM
Cell Processing Track Session 3 - Cell Product Characterization I
Chair:
Ruud Hulspaas, PhD , Cellular Technologies Bioconsulting, United States
Speakers:
Tamara Laskowski, PhD, MD Anderson Cancer Center, United States
Heba Degheidy, MD, PhD , FDA, United States
01:00 PM - 02:30 PM
GRP Workshop Session 3 - Trial Design and Patient Cohorts
Moderator:
Karen Nichols, Esq, Vice President Regulatory and Quality, Magenta Therapeutics, United States
01:00 PM - 02:30 PM
ISCT-CBA Cord Blood Series Session 3 - Manufacturing Novel Cell Therapy Products from Cord and Blood Tissue
Speakers:
Carolyn Yeago, PhD, Georgia Institute of Technology, United States
Joanne Kurtzberg, MD, Duke University Medical Center, United States
Elizabeth J. Shpall, MD, MD Anderson Cancer Center, United States
01:00 PM - 02:30 PM
MSC Workshop Session 3 - “Responders” to MSC Therapy – Predicting Clinical Outcomes
Chair:
Katarina LeBlanc, MD, PhD, Karolinska University Hospital Huddinge, Sweden
Speakers:
Eleuterio Lombardo, PhD, TiGenix SAU, Spain
Michael Matthay, MD, University of California San Francisco, United States
01:00 PM - 02:30 PM
Canadian Cell Therapy Strategy Workshop Session 3 - Making Frontline Life-Saving Therapies Economically Feasible
01:00 PM - 02:30 PM
ISCT-FACT Quality Bootcamp Session 3
02:45 PM - 04:00 PM
ISCT-FACT Quality Bootcamp Session 4
02:45 PM - 04:15 PM
Cell Processing Track Session 4 - Cell Product Characterization II
Chair:
Ruud Hulspaas, PhD, Cellular Technologies Bioconsulting, United States
Speakers:
J. Joseph Melenhorst, PhD, University of Pennsylvania, United States
02:45 PM - 04:15 PM
GRP Workshop Session 4 - Biological Variation and Cell Product Efficacy
02:45 PM - 04:15 PM
ISCT-CBA Cord Blood Series Session 4 - Cord Blood for Regenerative Medicine
Speakers:
Joanne Kurtzberg, MD, Duke University Medical Center, United States
02:45 PM - 04:15 PM
MSC Workshop Session 4 - Summary and Discussion
Chair:
Jacques Galipeau, MD, FRCP(C), University of Wisconsin-Madison, United States
02:45 PM - 04:15 PM
Canadian Cell Therapy Strategy Workshop Session 4 - Strengthening the Canadian RMCT Ecosystem
04:30 PM - 06:30 PM
Corporate Symposium Hosted by Miltenyi Biotec

Thursday, May 3

07:30 AM - 08:30 AM
Hot Topic Session 1 - Tregs and Other Immunotherapy in Autoimmune Disease
Chair:
David DiGiusto, PhD, Stanford Healthcare and Stanford School of Medicine, United States
Speaker:
Everett Meyer, MD, PhD, Stanford Healthcare and Stanford University, United States
Alan Burns, PhD Takeda Pharmaceuticals, United States
07:30 AM - 08:30 AM
Hot Topic Session 2 - Basic Approach to Overcoming Limitations of Cell Therapies
Chair:
Sandeep Soni, MD, Stanford University, United States
Speakers:
Philip Gregory, PhD, bluebird bio, United States
Judith Anne Shizuru, MD, PhD, Stanford University Medical Center, United States
Daniel Shoemaker, PhD , Fate Therapeutics, United States
07:30 AM - 08:30 AM
Sponsored Breakfast Corporate Tutorial - GE Healthcare
09:00 AM - 10:30 AM
Presidential Plenary on Cancer Immunotherapy
Chair:
Catherine Bollard, MBChB, MD, Children's National Medical Center and The George Washington University, United States
Speakers:
Crystal Mackall, MD, Stanford University School of Medicine, United States
Stanley Riddell, MD, Fred Hutchinson Cancer Research Center, United States
Robert Negrin, MD, Stanford University School of Medicine, United States
11:00 AM - 12:15 PM
Plenary Breakout - Cancer Immunotherapy I
Chair:
Crystal Mackall, MD, Stanford University School of Medicine, United States

Selected Oral Abstract Presentations
11:00 AM - 12:15 PM
Plenary Breakout - Cancer Immunotherapy II
Chair:
Robert Negrin, MD, Stanford University School of Medicine, United States

Selected Oral Abstract Presentations
11:00 AM - 12:15 PM
Strategies for Commercialization Track Session 1 - Future Proofing Your Supply Chain; Using the Lessons of the Past to Create Commercially Viable Logistics Platforms for the Future
Chair:
Simon Ellison, MBA, World Courier, United Kingdom
Speakers:
Sven Kili, MBChB, GSK Gene Therapy, United Kingdom
Christina Yi, Dendreon, United States
Robert Preti, PhD, Hitachi Chemical Advanced Therapeutics Solutions, United States

This session will use MACI, Strimvelis and Provenge as applied examples, then overlay the broader view of a CMO to identify lessons learned and suggest what supply chains of the future should look like.
Highlighting topics such as how to manage:
- Cost by reducing complexity
- Vein to vein journey as a single inter-related system
- Scale up/out by utilizing a logistics platform early in the development pathway
Tracks(s): Strategies for Commercialization Track
11:00 AM - 12:15 PM
Strategies for Commercialization Track Session 2 - How do Clinical Trial Design and Subsequent Learnings Impact Commercialization?
Chair:
Uri Herzberg, DVM, PhD, MBA, Celularity, United States
Speakers:
Robert Willie Mays, PhD, Athersys, United States
Steven Fischkoff, MD, WindMIL Therapeutics, United States
Monica Luchi, MD, FACR, MBA, Celularity, United States

As cell therapy is coming of age, it is evident that along the clinical opportunity, successful commercialization could be a major challenge. Hence, the design of clinical trials, in addition to including the endpoints required for registration, must address elements needed for commercialization. The session objectives will be to share the learnings and experiences of seasoned clinical leaders in the field and highlight the challenges that must still be addressed.
Specific objectives will include the following:
- Adequate Clinical design is key to getting to the appropriate patient profile for best response to the product. Specifically as reimbursement is easier for the patient that shows greater clinical benefit. Examples include patients sub-population in stroke, disease stage in diabetes, and disease severity in Crohn’s
- Similarly, side effects, dosing and treatment expectations for physician and patients are important when formulating care givers’ education around efficacy and safety / side effects, prior to commercialization
- Supply chain issues, formulations, efficiencies in every stage of the product life cycle training of health care providers as well as elements yet unknown (what we “do not know that we don’t know”)
Tracks(s): Strategies for Commercialization Track
11:00 AM - 12:15 PM
Quality and Operations Track Session 1 - Progress in the World of Standards for Cell and Gene Therapies
Chair:
Sowmya Viswanathan, PhD, University Health Network, University of Toronto, Canada
Speakers:
Jiwen Zhang, PhD, GE Healthcare, United States
Claudia Zylberberg, PhD, Akron Biotech, United States
Julian Braybrook, PhD, LGC, United Kingdom
Tatsuo Heki, Fujifilm Corporation, Japan
Tracks(s): Quality and Operations Track
11:00 AM - 12:15 PM
Advanced Practice Professionals Session 1
Tracks(s): Advanced Practice Professionals Track
12:30 PM - 01:30 PM
Corporate Tutorial Hosted by BD Biosciences
01:45 PM - 03:15 PM
Plenary Session 2 - Mesenchyme Biology and Translational Use
Chair:
Jacques Galipeau, MD, University of Wisconsin-Madison, United States
Speakers:
Martin Hoogduijn, PhD, Erasmus MC, University Medical Center Rotterdam, Netherlands
Bruno Péault, PhD, University of Edinburgh, Scotland, and University of California at Los Angeles, United States
Duncan Stewart, MD, The Ottawa Hospital Research Institute, Canada
03:45 PM - 05:00 PM
Plenary Breakout - Endothelial Progenitor Cells
Chair:
Duncan Stewart, MD, The Ottawa Hospital Research Institute, Canada
Speaker:
Bernard Thébaud, MD, PhD, The Ottawa Hospital Research Institute, Canada

Selected Oral Abstract Presentations
03:45 PM - 05:00 PM
Plenary Breakout - Mesenchymal Stem Cells
Chair:
Bruno Péault, PhD, University of Edinburgh, Scotland, and University of California at Los Angeles, United States
Speakers:
Jacques Galipeau, MD, University of Wisconsin-Madison, United States
Michael Matthay, MD , University of California San Francisco, United States

Selected Oral Abstract Presentations
03:45 PM - 05:00 PM
Quality and Operations Track Session 2 - Applying Change Within Controlled Systems and Processes
Chair:
Rosemarie Bell, BAppSc Micro/Biochem MASM, QIMR Berghofer Medical Research Institute, Australia
Speakers:
Steven Kiezer, MBA, CCRM, Canada
Day (Bangon) Longsomboon, MA, Interdisciplinary Stem Cell Institute, United States
Gerry McKiernan, BSc, Cell Therapies PTY Ltd, Australia

As technologies evolve and new methods of improved manufacturing are developed, we need to be able to implement these new process changes into our clinical manufacturing to deliver the best possible outcome for patients and not be confined to the processes that were deployed in early phase development if they become outdated. Leading on from the what and the why, this presentation will discuss how you manage a major change to a new cell expansion platform during a phase III clinical trial, the wide range of impacts you need to consider and how you manage implementation to maintain a state of control.
Tracks(s): Quality and Operations Track
03:45 PM - 05:00 PM
Advanced Practice Professionals Session 2
Tracks(s): Advanced Practice Professionals Track
03:45 PM - 05:00 PM
Scientific Area of Focus Session - Stem Cell Biology and Expansion
Chair:
John Rasko, AO, BSc(Med), MBBS(Hons), PhD, MAICD, FFSc(RCPA), FRCPA, FRACP, FAHMS, Royal Prince Alfred Hospital, Australia
Speakers:
Colleen Delaney, MD, MSc, Nohla Therapeutics, United States
Guy Savageau, MD, PhD , University of Montreal, Canada
Shahin Rafii, MD, Weill Cornell Medical College, United States
03:45 PM - 05:00 PM
Chief Scientific Officer Abstract Showcase
05:00 PM - 06:30 PM
Advanced Practice Professionals Session 3
Tracks(s): Advanced Practice Professionals Track
05:00 PM - 07:00 PM
Corporate Symposium Hosted by Novartis Oncology - What Makes CARs Work? — A Look Under the Hood
Chair:
Marcela Maus, MD, PhD, Massachusetts General Hospital, United States
Speakers:
John Bell, PhD, The Ottawa Hospital, University of Ottawa, Canada
Karen Thudium, MD, Novartis Pharmaceuticals, United States
Bijal Shah, MD, Moffitt Cancer Center, United States
05:30 PM - 07:00 PM
Poster Session 1

Friday, May 4

07:30 AM - 08:30 AM
Hot Topic Session 3 - Immunologic Sculpting of HSCT and Grafts
Chair:
Denis-Claude Roy, MD, FRCPC, University of Montreal, Canada
Speakers:
Denis-Claude Roy, MD, FRCPC, University of Montreal, Canada
Isabelle Riviere, PhD, Memorial Sloan Kettering Cancer Center, United States
Alice Bertaina, MD, PhD, Stanford School of Medicine, United States
07:30 AM - 08:30 AM
Hot Topic Session 4 - Oncolytic Viruses
Chair:
John Bell, PhD, The Ottawa Hospital, University of Ottawa, Canada
Speakers:
John Bell, PhD, The Ottawa Hospital, University of Ottawa, Canada
Khalid Shah, MS, PhD, Harvard Medical School, United States
07:30 AM - 08:30 AM
Sponsored Breakfast Corporate Tutorial
08:45 AM - 10:15 AM
Plenary Session 3 - Exosomes
Chair:
Daniel J. Weiss, MD, PhD, University of Vermont School of Medicine, United States
Speakers:
Eva Rohde, MD, Paracelsus Medical University, Austria
Linda Marban, PhD, Capricor, United States
Sai-Kiang Lim, PhD, A*STAR Institute of Medical Biology, Singapore
10:45 AM - 12:15 PM
Plenary Breakout - Exosome Technology
Chair:
Eva Rohde, MD, Paracelsus Medical University, Austria
Speakers:
Chulhee Choi, MD, PhD, KAIST, Korea
Randolph Corteling, PhD, ReNeuron, United Kingdom

Selected Oral Abstract Presentations
10:45 AM - 12:15 PM
Plenary Breakout - Clinical Trial Site Learning as it Applies to CAR T Commercial Roll Out
Chair:
Sarah Nikiforow, MD, PhD, Dana Farber Cancer Institute, United States
Speakers:
Sarah Nikiforow, MD, PhD, Dana Farber Cancer Institute, United States
Solveig Ericson, MD, PhD, Novartis, United States
Diane Parks, MBA Kite Pharma Inc, United States
10:45 AM - 12:15 PM
Strategies for Commercialization Track Session 3 - Tools and Automation Solutions for Accelerating Cell and Gene Therapy Development
Chair:
Julie Murrell, PhD, MilliporeSigma, United States
Speakers:
Qasim Rafiq, PhD, University College London, United Kingdom
Jon Rowley, PhD, RoosterBio, United States
Greg Russotti, PhD, Celgene, United States

With recent approvals, the urgency for improvements in Cell and Gene Therapy Development are even more immediate than in the past. Here, we have perspectives from academia, biotech and suppliers:
- What are the drivers for change?
- What sort of technologies and innovations do we use to develop new products and reagents?
- How can we implement these tools into the development cycle?
A panel discussion will follow the speaker presentations and will be open to audience questions.
Tracks(s): Strategies for Commercialization Track
10:45 AM - 12:15 PM
Quality and Operations Track Session 3 - Regulation of MTMMS and ATMPS: Manufacturing, Non-Clinical, and Clinical Perspectives
Chair:
Shirley Bartido, PhD, MBA, Cellectis, United States
Speakers:
Shirley Bartido, PhD, MBA, Cellectis, United States
Julianne Smith, PhD, Cellectis, France
Elena Spanjaard, PhD, Pfizer, United States
Tracks(s): Quality and Operations Track
10:45 AM - 12:15 PM
Scientific Area of Focus - NK Cells
Chair:
Armand Keating, MD, Princess Margaret Hospital, Canada
Speakers:
Sarah Cooley, MD, University of Minnesota Department of Medicine, United States
Katy Rezvani, MD, PhD, , MD Anderson Cancer Center, United States
Armand Keating, MD, Princess Margaret Hospital, Canada
10:45 AM - 12:15 PM
ISCT Presidential Task Force Session
12:30 PM - 01:30 PM
Corporate Tutorial Hosted by Macopharma
01:45 PM - 03:15 PM
Plenary Session 4 - Pathways to Progress: Delivering on the Promise of CAR-T Therapies
Chair:
Miguel Forte, MD, PhD, Zelluna Immunotherapy, Belgium
Speakers:
CAR T: Current Status and Perspectives from the Academic Lens
Carl June, MD, University of Pennsylvania, United States
Reimagining Cancer Care and Delivering Kymriah to Patients
Pascal Touchon, DVM, MBA Novartis, United States
Diane Parks, MBA, Kite Pharma Inc, United States


The session aims at enable the understanding, comparison and discussion of different models of academic to industrial translation through recent CAR-T breakthroughs as leading examples of successful translation of impressive clinical data to commercial cell and gene therapy products.
The challenges, opportunities and lessons learned from the translation and present and planned commercialization of CAR-T products in the US and globally will also be discussed.
The session represents a unique opportunity to engage with the speakers and discuss these successful examples that show how cell and gene therapy is bringing value to patients with unmet medical with wide implications in different sectors of the cell and gene therapy field.
03:30 PM - 05:00 PM
Plenary Breakout - Pre-Clinical Application of Exosomes
Chair:
Linda Marban, PhD,Capricor, United States
Speakers:
Lambros Kordelas, PhD, University Hospital Essen, Germany
Marie-Josée Hébert, MD, FRCPC, University of Montreal, Canada

Selected Oral Abstract Presentations
03:30 PM - 05:00 PM
Plenary Breakout - Market Access & Reimbursement of CAR T Therapies
Chair:
Dawn Driscoll, PhD, MBA, Cell Therapies PTY, Australia
Speakers:
Michele Korfin, MBA, Kite Pharma, United States
Douglas Olson, PhD, United States
Dan Ollendorf, PhD, Institute for Clinical and Economic Review (ICER), United States
03:30 PM - 05:00 PM
Strategies for Commercialization Track Session 4 - 21st Century Global Regulatory Impact with Divergent Markets on Commercialization
Chair:
Julie Allickson, PhD, Wake Forest Institute for Regenerative Medicine, United States
Speakers:
Flagg Flanagan, DiscGenics, United States
Rainer Marksteiner, PhD, Innovacell, Austria
Bao-Zhu Yuan, PhD National Institutes for Food and Drug Control, China
John Martin, Regeneus, Australia
Panelists:
Michael Mendicino, PhD, Hybrid Concepts International, United States
Colin Novick, CJ Partners, Japan
Tracks(s): Strategies for Commercialization Track
03:30 PM - 05:00 PM
Quality and Operations Track Session 4 - Day to Day Operations of a Stem Cell Lab
Chair:
Heather Garrity, BA, MHA, Dana Farber Cancer Institute, United States
Speakers:
Karl Stasko, MPH, Dana Farber Cancer Institute, United States
Joseph Schwartz, MD, MPH, Columbia University Medical Center, United States
Christine Rosati, Boston's Children's Hospital, United States
Tracks(s): Quality and Operations Track
03:30 PM - 05:00 PM
Early Stage Professionals Session 1
03:30 PM - 05:00 PM
ISCT 2018 Organizing Committee Abstract Showcase
05:00 PM - 06:30 PM
Poster Session 2

Saturday, May 5

08:00 AM - 09:00 AM
Hot Topic Session 5 - Solid Organ Transplantation: Tolerance Induction and Tregs Immunotherapy
Chair:
Stephan Busque, MD, Stanford University, United States
Speakers:
Stephan Busque, MD, Stanford University, United States
Joseph Leventhal, MD, Northwestern Medicine, United States
08:00 AM - 09:00 AM
Hot Topic Session 6 - Biomaterials and clinical Uses
Chair:
May Griffith, PhD, MBA, University of Montreal, Canada
08:00 AM - 09:00 AM
Strategies for Commercialization Track Session 5 - Managing Patient Expectations
Chair:
Gerhard Bauer, PhD, UC Davis, United States
Speakers:
Gerhard Bauer, PhD, UC Davis, United States
Dawn Driscoll, PhD, MBA, Cell Therapies PTY, Australia
Douglas Olson, PhD, United States
Tracks(s): Strategies for Commercialization Track
08:00 AM - 09:00 AM
Quality and Operations Track Session 5 - Data Integrity
Chair:
Gabrielle O'Sullivan, PhD, MPH, Royal Prince Alfred Hospital, Australia
Speakers:
Zlatibor Velickovic, PhD, Royal Prince Alfred Hospital, Australia
Alex Denoon, LLB Marriott Harrison UK, United Kingdom
Matthew Lakelin, PhD, TrakCel, United Kingdom
James Blackwell, PhD, MBA, The Windshire Group, United States
Tracks(s): Quality and Operations Track
09:15 AM - 10:45 AM
Plenary Session 5 - ISCT-ASGCT Joint Session: Genome Editing
Co-Chairs:
Donald Kohn, MD, University of California, Los Angeles, United States
Helen Heslop, MD, Baylor College of Medicine, United States
Speakers:
Matthew Porteus, MD, PhD, Stanford University School of Medicine, United States
John Zaia, MD, City of Hope, United States
Michael Holmes, PhD, Sangamo Therapeutics, United States
11:00 AM - 12:00 PM
Plenary Breakout - Ex Vivo Editing - HSC and iPSC
Chair:
Matthew Porteus, MD, PhD, Stanford University School of Medicine, United States
Speaker:
Donald Kohn, MD, University of California, Los Angeles, United States

Selected Oral Abstract Presentations
11:00 AM - 12:00 PM
Plenary Breakout - Editing to Enhance Cell Therapy - Universal T Cells
Chair:
Helen Heslop, MD , Baylor College of Medicine, United States
Speaker:
Andrew Scharenberg, MD, University of Washington, United States

Selected Oral Abstract Presentations
11:00 AM - 12:00 PM
Strategies for Commercialization Track Session 6 - Growing the Pie: Has Investor Interest Increased for CGT post-approval of Kymriah, Yescarta and Luxturna?
Chair:
Bill Milligan, Steminent Biotherapeutics, Canada
Speakers:
Patrick Rivers, MBA, Aquilo Capital, United States
Kanishka Pothula, MS, BVF Partners, United States
Didier Leconte, MBA, FSTQ, Canada

How have the recent approvals of these two CD19 CAR T therapies and gene therapy influenced investor behaviour? In this session, we'll look at how investors perceive and value CGT investments versus other more traditional
treatment modalities and explore what their biggest remaining concerns might be. In addition, we’ll explore how to identify and engage the right investors and how to optimally position your company to raise capital.
A must attend session in understanding what has changed for investors and how to leverage it going forward.
Tracks(s): Strategies for Commercialization Track
11:00 AM - 12:00 PM
Quality and Operations Track Session 6 - Maintenance of a GMP Facility
Chair:
Nadim Mahmud, MD, PhD, University of Illinois Hospital and Health Sciences System, United States
Speakers:
Nadim Mahmud, MD, PhD, University of Illinois Hospital and Health Sciences System, United States
Aisha Khan, MBA, University of Miami, United States
Tracks(s): Quality and Operations Track
11:00 AM - 12:00 PM
Early Stage Professionals Session 2 - Young Investigator Abstract Showcase
01:30 PM - 03:00 PM
Plenary Session 6 - iPSC Regenerative Medicine
Speaker:
Andras Nagy, PhD, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Canada
03:15 PM - 04:30 PM
Plenary Breakout 1 - iPSC and Organogenesis
Speakers:
Timothy J. Kieffer, University of British Columbia, Canada
03:15 PM - 04:30 PM
Plenary Breakout 2 - iPSC and ESC
Speakers:
Jean Tang, MD, PhD, Stanford University School of Medicine, United States
03:15 PM - 04:30 PM
Strategies for Commercialization Track Session 7 - ISCT-BPSA Joint Session Next Generation Manufacturing for Cell and Gene Therapies
ISCT-BPSA Joint Session
Tracks(s): Strategies for Commercialization Track
03:15 PM - 04:30 PM
Quality and Operations Track Session 7 - Regulatory Expectations for the Manufacturing Control Strategy
Co-Chairs:
Rosemarie Bell, BAppSc Micro/Biochem MASM, QIMR Berghofer Medical Research Institute, Australia
Sowmya Viswanathan, PhD, University Health Network, University of Toronto, Canada
Speaker:
Karin Hoogendoorn, PharmD, Leiden University Medical Centre, Netherlands
Tracks(s): Quality and Operations Track